non-targeting control gRNA (BRDN0001149198) Citations (3)

Originally described in: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.
Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE Nat Biotechnol. 2016 Jan 18. doi: 10.1038/nbt.3437. PubMed Journal

---

Articles Citing non-targeting control gRNA (BRDN0001149198)

Articles
Using CRISPR Interference as a Therapeutic Approach to Treat TGFbeta2-Induced Ocular Hypertension and Glaucoma. Rayana NP, Sugali CK, Dai J, Peng M, Liu S, Zhang Y, Wan J, Mao W. Invest Ophthalmol Vis Sci. 2021 Sep 2;62(12):7. doi: 10.1167/iovs.62.12.7. PubMed
CaMKK2 is not involved in contraction-stimulated AMPK activation and glucose uptake in skeletal muscle. Negoita F, Addinsall AB, Hellberg K, Bringas CF, Hafen PS, Sermersheim TJ, Agerholm M, Lewis CTA, Ahwazi D, Ling NXY, Larsen JK, Deshmukh AS, Hossain MA, Oakhill JS, Ochala J, Brault JJ, Sankar U, Drewry DH, Scott JW, Witczak CA, Sakamoto K. Mol Metab. 2023 Sep;75:101761. doi: 10.1016/j.molmet.2023.101761. Epub 2023 Jun 26. PubMed
PACT suppresses PKR activation through dsRNA binding and dimerization, and is a therapeutic target for triple-negative breast cancer. Young AA, Juhler IG, Pierce JR, Bohlin HE, Harper HA, Onishile DS, Chua RN, Liu ME, Gardner EN, Elzey BD, Cottrell KA. RNA. 2025 Oct 16;31(11):1599-1618. doi: 10.1261/rna.080637.125. PubMed

If you have published an article using this material, please email us at to have your article added to this page.